Novel pharmacologic therapies in development for acute decompensated heart failure

Current Cardiology Reports

Volumn 15, Issue 2, 2013, Pages

  Ezekowitz, Justin A ^a,b  

^a MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acute decompensated heart failure; Clinical trials; Pharmacologic therapy

Indexed keywords

ALADORIAN; ALISKIREN; ATRIAL NATRIURETIC FACTOR ALPHA; CENDERITIDE; CINACIGUAT; DOPAMINE; FUROSEMIDE; ISTAROXIME; NESIRITIDE; OMECAMTIV MECARBIL; PLACEBO; RELAXIN; TOLVAPTAN; URODILATIN; ATRIAL NATRIURETIC FACTOR; DIURETIC AGENT; DRUG DERIVATIVE; PEPTIDE FRAGMENT; UREA; VASODILATOR AGENT;

ACUTE HEART FAILURE; ARTICLE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LOW DRUG DOSE; MORBIDITY; MORTALITY; RENAL PROTECTION; ACUTE DISEASE; HEART FAILURE; REVIEW;

ACUTE DISEASE; ATRIAL NATRIURETIC FACTOR; DIURETICS; HEART FAILURE; HUMANS; PEPTIDE FRAGMENTS; RELAXIN; UREA; VASODILATOR AGENTS;

MLCS; MLOWN;

EID: 84879322550     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0329-z     Document Type: Article

References (39)

1. Ezekowitz JA, Kaul P, Bakal JA, Quan H, McAlister FA. Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics? Eur J Heart Fail. 2011;13(2):142-7.
2. Baggish A, Siebert U, Lainchbury J, Cameron R, Anwaruddin S, Chen A, Krauser D, Tung R, Brown D, Richards A. A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J. 2006;151(1):48-54. (Pubitemid 41815330)
3. Moe GW, Howlett J, Januzzi JL, Zowall H, for the Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-Terminal pro-B-Type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007;115(24):3103-10. (Pubitemid 46956499)
4. Arnold JMO, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. In: Can J Cardiol. 2007; 21-45. (Pubitemid 46403407)
5. Allen LA, Hernandez AF, O'Connor CM, Felker GM. End points for clinical trials in acute heart failure syndromes. JAC. 2009;53 (24):2248-58. A good review of the issues that are important to AHF clinical trials such the endpoint selection and meaning.
6. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883-91. (Pubitemid 46707842)
7. Cuffe MS, Califf RM, Adams KF, et al. Short-Term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(12):1541-7. (Pubitemid 34269999)
8. Micheletti R, Mattera GG, Rocchetti M, et al. Pharmacological profile of the novel inotropic agent (E, Z)-3-((2-Aminoethoxy) imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther. 2002;303(2):592-600. (Pubitemid 35231230)
9. Khan H, Metra M, Blair JEA, Vogel M, Harinstein ME, Filippatos GS, Sabbah HN, Porchet H, Valentini G, Gheorghiade M. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev. 2009;14(4):277-87.
10. Gheorghiade M, Blair JEA, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51(23):2276-85.
11. Ceholski DK, Trieber CA, Holmes CFB, Young HS. Lethal, hereditary mutants of phospholamban elude phosphorylation by protein kinase a. J Biol Chem. 2012;287(32):26596-605. Outlines the importance of the calcium handling system and what happens when parts are missing such as heridary mutations.
12. Scoote M, Williams AJ. The cardiac ryanodine receptor (calcium release channel): emerging role in heart failure and arrhythmia pathogenesis. Cardiovas Res. 2002;56(3):359-72. (Pubitemid 35351558)
13. Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331(6023):1439-43. The key reference for the most important advance in inotropic therapy in over 2 decades.
14. Cleland JGF, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378(9792):676-83.
15. Nomura F, Kurobe N, Mori Y, Hikita A, Kawai M, Suwa M, Okutani Y. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J. 2008;72(11):1777-86.
16. Sato N, Kajimoto K, Asai K, et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J. 2010;159(6):949. 955.e1.
17. Hata N, Seino Y, Tsutamoto T, et al. Effects of carperitide on the long-Term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008;72(11):1787-93. The only quality RCTsupporting this drugs use. Despite the lack of evidence, this drug is used widely in Japan.
18. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32-43. By far the largest RCT in AHF, and one with key design elements now being emulated by other RCT. Designed and operationalized by an academic consortium with industry partner.
19. Forssmann W, Meyer M, Forssmann K. The renal urodilatin system: clinical implications. Cardiovas Res. 2001;51(3):450-62. (Pubitemid 32718593)
20. Mitrovic V, Lüss H, Nitsche K, Forssmann K, Maronde E, Fricke K, Forssmann W-G, Meyer M. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J. 2005;150(6):1239.
21. Mitrovic V, Seferovic PM, Simeunovic D, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27(23):2823-32. (Pubitemid 44871466)
22. Lüss H, Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Moiseyev VS, Forssmann W-G, Hamdy AM, Meyer M. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J. 2008;155(6):1012.e1-8.
23. Costello-Boerrigter LC, Schirger JA, Miller WL, Boerrigter G, Chen HH, Kempf R, Lee CY, Burnett JC. Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-ofconcept study in patients with chronic heart failure. BMC Pharmacol. 2011;11 Suppl 1:p18.
24. Lieu HD, Young J, Elkayam U, Katz A, Darius H, Goldstein S, Massie B, Costello-Boerrigter L, Burnett J. A phase ii, doseranging study with cd-np, a chimeric natriuretic peptide, in acute decompensated heart failure patients with renal compromise. JAC. 2011;57(S):E2029.
25. Jeyabalan A, Shroff SG, Novak J, Conrad KP. The vascular actions of relaxin. Adv Exp Med Biol. 2007;612:65-87.
26. Debrah DO, Conrad KP, Jeyabalan A, Danielson LA, Shroff SG. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension. 2005;46(4):745-50. (Pubitemid 43186748)
27. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dosefinding phase IIb study. Lancet. 2009;373(9673):1429-39. Major finding for vasodilators in AHF -one that works well without significant harm.
28. Ponikowski P, Metra M, Teerlink JR, et al. Design of the RELAXin in acute heart failure study. Am Heart J. 2012;163(2):149-55.e1.
29. Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, Mebazaa A. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J. 2012. doi:10.1093/eurheartj/ehs196.
30. Voors AA, Van Veldhuisen DJ. Why do drugs for acute heart failure fail? Eur J Heart Fail. 2012;14(9):955-6.
31. Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A, on behalf of the COMPOSE Investigators and Coordinators. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail. 2012;14(9):1056-66.
32. Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363(15):1419-28. A big trial that missed on the key renal protection it was supposed to provide.
33. Giamouzis G, Butler J, Starling RC, Karayannis G, Nastas J, Parisis C, Rovithis D, Economou D, Savvatis K, Kirlidis T. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) trial. J Card Fail. 2010;16(12):922-30.
34. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319-31. (Pubitemid 46513233)
35. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669-77.
36. McMurray JJV, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J. Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1(1):17-24.
37. Gheorghiade M, Albaghdadi M, Zannad F, et al. Rationale and design of the multicentre, randomized, double-blind, placebocontrolled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail. 2011;13(1):100-6. Unclear if yet another RAAS blocker will fail in this complicated area.
38. Armstrong PW, Ezekowitz JA. Testosterone therapy in women with heart failure "why can't a woman be more like a man?". J Am Coll Cardiol. 2010;56(16):1317-9.
39. Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev. 2007;12 (2):87-90. (Pubitemid 46916952)